- Home
- FEBO vs ICU Comparison
FEBO vs ICU Comparison
Compare FEBO & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FEBO | ICU |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4M | 9.1M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | FEBO | ICU |
|---|---|---|
| Price | $0.81 | $4.78 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.6K | ★ 118.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $0.22 |
| 52 Week High | $1.46 | $5.38 |
Technical Indicators
Market Signals| Indicator | FEBO | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 42.07 | 67.38 |
| Support Level | $0.71 | $2.32 |
| Resistance Level | $1.25 | $4.96 |
| Average True Range (ATR) | 0.07 | 0.49 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 21.84 | 79.34 |
Price Performance
Historical ComparisonAbout FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.